Clinical trial
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
NCT00245024 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00245024 |
|---|---|
| Title | Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer |
| Official title | Phase IB Sulindac Study for Women at High Risk for Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | University of Arizona |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | sulindac, laboratory biomarker analysis |
| Enrollment | 30 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Oct 27, 2005 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: